Characterisation of liver fat in the UK Biobank cohort
by Henry R. Wilman, Matt Kelly, Steve Garratt, Paul M. Matthews, Matteo Milanesi, Amy Herlihy, Micheal Gyngell, Stefan Neubauer, Jimmy D. Bell, Rajarshi Banerjee, E. Louise Thomas Non-alcoholic fatty liver disease and the risk of progression to steatohepatitis, cirrhosis and hepatocellular carcinoma have been identified as major public health concerns. We have demonstrated the feasibility and potential value of measuring liver fat content by magnetic resonance imaging (MRI) in a large population in this study of 4,949 participants (aged 45–73 years) in the UK Biobank imaging enhancement. Despite requirements for only a single (≤3min) scan of each subject, liver fat was able to be measured as the MRI proton density fat fraction (PDFF) with an overall success rate o f 96.4%. The overall hepatic fat distribution was centred between 1–2%, and was highly skewed towards higher fat content. The mean PDFF was 3.91%, and median 2.11%. Analysis of PDFF in conjunction with other data fields available from the UK Biobank Resource showed associations of increased liver fat with greater age, BMI, weight gain, high blood pressure and Type 2 diabetes. Subjects with BMI less than 25 kg/m2 had a low risk (5%) of high liver fat (PDFF> 5.5%), whereas in the higher BMI population (>30 kg/m2) the prevalence of high liver fat was approximately 1 in 3. These data suggest that population screening to identify people with high PDFF is possible and could be cost effective. MRI bas...
Abstract: The US industrial revolution led to a significant increase in the amount of dietary sugar consumed annually. The impact has become a public health crisis over the past several decades. The consequences are seen in the dramatic rise in rates of obesity, type 2 diabetes mellitus, and cardiovascular disease.
The drug, Rybelsus (semaglutide) is the first pill in a class of drugs called glucagon-like peptide (GLP-1) approved for use in the United States. Before Rybelsus, the drug had to be injected.
ConclusionsExperts compared therapeutic attitudes and practices regarding second-line treatment failure between French regions. They identified convergences that were used to propose a national agreement on second-line treatment failure criteria, which should be evaluated in real-life prospective cohorts.
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
Liver disease constitutes the third most common cause of premature death in the UK, and its prevalence is substantially higher compared to other countries in Western Europe.[1 –3] Excess liver iron is associated with increased severity and progression of liver diseases including cirrhosis and hepatocellular carcinoma in individuals with non-alcoholic fatty liver disease (NAFLD), [4–6] and is the direct cause of liver disease in those with hereditary haemochromatosis a nd thalassaemia.[7,8] Observational associations have been described between excess liver iron content and several metabolic diseases such as hig...
AbstractPurpose of ReviewIn this review, we examine the interaction between the metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) and describe the impact of the features of MS on the most worrisome complications of non-alcoholic steatohepatitis (NASH), (cirrhosis, hepatocellular carcinoma) and, ultimately, on liver-related, cardiovascular, and overall mortality.Recent FindingsInsulin resistance, obesity, and dyslipidemia in a pro-inflammatory environment have a causal role in hepatic fibrogenesis and oncogenesis in NAFLD patients. Natural history, longitudinal studies confirm the conditions linked to MS...
CONCLUSION: Type 2 diabetes mellitus plays an important role in the progression of non-alcoholic fatty liver disease as an independent risk factor for severe fibrosis. PMID: 29893699 [PubMed - in process]
Conclusion This cohort study aimed to assess whether a high BMI in late adolescence is associated with an increased risk of severe liver disease and liver cancer in later life. The researchers generally found a higher BMI was associated with an increased risk of severe liver disease, including liver cancer. A diagnosis of type 2 diabetes during follow-up was associated with a further increased risk of severe liver disease, regardless of BMI at the start of the study. This study included a very large population, and has used reliable sources of data for medical diagnoses and cause of death. But there are limitations to ...
Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2015)
Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of the metabolic syndrome, which is characterized by insulin resistance, dyslipidemia, hypertension and type 2 diabetes [1,2]. It occurs mainly due to fat accumulation in the liver, and can lead to cirrhosis, which is not reversible and may ultimately progress to hepatocellular carcinoma (HCC) [3,4]. Several population-based studies have demonstrated that the prevalence of NAFLD in premenopausal women is lower than that in men between the ages of 20 and 50years, and also lower than in postmenopausal women [5,6].
More News: Alcoholism | Biomedical Science | Cancer & Oncology | Carcinoma | Cirrhosis | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Hepatocellular Carcinoma | Hypertension | International Medicine & Public Health | Liver | Liver Cancer | Liver Disease | MRI Scan | Non-alcoholic Fatty Liver Diseases (NAFLD) | PET Scan | Study | Urology & Nephrology